Emerging markets set to outperform US stocks as dollar weakness continues, Cambridge says


Global investors should consider reducing their US equities exposure as emerging market stocks are on track to outperform those in developed nations for the first time in five years amid a weakening US dollar, according to global investment firm Cambridge Associates.

The recommendation comes as the dollar has experienced significant weakness this year, falling by 10 per cent at one point after a decade-long bull run that started in 2011.

However, the greenback still remains 29 per cent above its median real valuation. “We expect the dollar to decline further in 2026”, beginning a multi-year bear market, Boston-based Cambridge said, citing headwinds from uncertainty in economic policy, overvalued assets, and fiscal pressures that could dampen global demand for the US dollars.

The weaker US dollar has benefited international stocks. Global non-US equities outperformed US equities by 6.6 percentage points in local currency terms in 2025, and by 13.9 percentage points in US dollar terms.

Tourists take photos in front of the bull statue in Shanghai, August 7, 2025. Photo: EPA
Tourists take photos in front of the bull statue in Shanghai, August 7, 2025. Photo: EPA

Cambridge expected this trend to continue and recommended that investors be overweight in global non-US equities in 2026.

Latin America, which has been an underappreciated market for many years with valuations near 20-year lows, was the stand-out performer in emerging markets, with a 37 per cent year-to-date return on equities. The region was expected to offer further outperformance potential, supported by deeply discounted equity and currency valuations and improving macroeconomic conditions, the report said.

  • Related Posts

    Surging oil prices drive Hong Kong stocks to 6-month low on inflation jitters

    Hong Kong stocks fell to a six-month low on Wednesday, as surging oil prices fuelled bets that rising energy costs would stoke inflation and increase the risk of a global…

    Continue reading
    Healthcare investors keeping an eye on ‘two sessions’ for clarity on drug pricing

    Ahead of China’s annual legislative meetings – typically a window into Beijing’s top-level policy agenda – this is the eighth entry in a series examining the complex economic recalibration driving…

    Continue reading

    Leave a Reply

    Your email address will not be published. Required fields are marked *